N/A
N=160
The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
Tissue Donors · Liver Transplantation · Ischemia Reperfusion Injury
Bottom Line
View on ClinicalTrials.gov: NCT03386435 ↗Enrolled (actual)
160
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days — 145; 152 IU/L
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- remote ischemic preconditioning (Procedure)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Asan Medical Center
- Primary completion
- Aug 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days |
145; 152 | — |
| PRIMARY The Maximal Alanine Aminotransferase Level Within 7 Postoperative Days |
148; 152 | — |
| SECONDARY Number of Participants With Delayed Recovery of Liver Function |
5; 0 | — |
| SECONDARY Postoperative Liver Regeneration |
83.3; 94.9 | — |
Summary
Liver transplantation is the gold standard treatment for patients with end-stage liver disease. Despite its outstanding success, liver transplantation still entails certain complications including ischemia-reperfusion injury. Remote ischemic preconditioning is a novel and simple therapeutic method to lessen the harmful effects of ischemia-reperfusion injury, however, the majority of remote ischemic preconditioning studies on hepatic ischemia-reperfusion injury have been animal studies. Therefore, our aim was to assess the effects of remote ischemic preconditioning on postoperative liver function in living donor hepatectomy.
Eligibility Criteria
Inclusion Criteria
- Donors who plan to have living right hepatectomy for liver transplantation.
- age : between 18 to 60 years.
Exclusion Criteria
- donors who plan to donate left lobe
- donors who plan to have laparoscopic right hepatectomy
- donors who cannot proceed remote ischemic preconditioning
Data sourced from ClinicalTrials.gov (NCT03386435). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.